On Friday, the U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals Holding Corp.’s (NASDAQ:TNXP) Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults.

Tonmya reduced daily pain scores in Phase 3 trials of nearly 1,000 patients. Tonix ended June with $125.3 million cash, funding operations into Q3 2026. Tonight: Get a FREE TRADE, built by the ...

Photo by Robina Weermeijer on Unsplash. A $1 million global competition that aims to accelerate Alzheimer’s disease research using AI launched today with support from Bill Gates and others. The ...

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Biogen Inc. is one of them. Biogen Inc. (NASDAQ:BIIB), founded in 1978 and headquartered in Cambridge, ...

Eli Lilly is promoting its Alzheimer’s medication Kisunla with a national ad campaign centered on hope for treating the disease as well as the importance of early detection and screening. Lilly’s ...

Primary care physicians (PCPs) in Ontario frequently used diagnostic tools to assess patients for Alzheimer’s disease and dementia, with usage increasing during follow-up. Antidepressants were ...

NEW YORK, Aug. 29, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...